Home › Trials › NCT06424106
Clinical trial Recruiting at 1 site Interventional Ages 25 to 65

Effects of glucagon on insulin secretion and glucose metabolism in people without diabetes

Official title: Effect of Glucagon on Fasting Insulin Secretion and Glucose Metabolism in Subjects Without Type 2 Diabetes

Run by Mayo Clinic · NCT06424106 · Data updated 2026-11-12

This study is testing how glucagon affects insulin and blood sugar levels in people who have normal or slightly high fasting glucose to better understand how to manage blood sugar.

More Prediabetes trials

Quick facts

Study typeInterventional
Ages25 Years to 65 Years
SexAll
Enrollment60 (estimated)
SponsorMayo Clinic
Academic / other
Locations1 site (Rochester, Minnesota)
StatusRecruiting
StartedApril 1, 2025
Main results expectedJuly 1, 2027
Study endsJuly 1, 2027
Registry record updatedApril 20, 2026
Trial IDNCT06424106 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are individuals with normal or impaired fasting glucose and normal or impaired glucose tolerance.

Probably not a fit

Patients with an HbA1c less than 6.5% or those currently using glucose-lowering agents will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates how glucagon and insulin interact to regulate fasting glucose levels in individuals with normal or impaired fasting glucose. It aims to understand the mechanisms behind fasting hyperglycemia, which is a significant contributor to complications in type 2 diabetes. The research will involve administering glucagon and glucose to assess their effects on insulin secretion and glucose metabolism. By exploring these interactions, the study seeks to fill gaps in knowledge regarding fasting glucose regulation in health and prediabetes.

Why it matters

Potential benefit: If successful, this study could lead to improved understanding and management of fasting glucose levels, potentially reducing the risk of developing type 2 diabetes.

How similar studies have gone: While the specific interactions being studied may not have been extensively tested, the investigation into glucagon's role in glucose metabolism is a relevant area of research with potential for significant findings.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Individuals with normal or impaired fasting glucose and normal or impaired glucose tolerance

Exclusion Criteria:

* HbA1c less than 6.5%
* Use of any glucose-lowering agents including metformin or sulfonylureas.
* For female subjects: positive pregnancy test at the time of enrollment or study
* History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy.
* Active systemic illness or malignancy.
* Symptomatic macrovascular or microvascular disease.

Where it's running

  • Mayo Clinic in Rochester
    Rochester, Minnesota, United States     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Prediabetes 131Mayo Clinic 511
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.